Literature DB >> 20964680

Potential clinical applications of siRNA technique: benefits and limitations.

Shao-Hua Chen1, Getu Zhaori.   

Abstract

BACKGROUND: RNA interference (RNAi) has become the method of choice for researchers wishing to target specific genes for silencing and has provided immense potential as therapeutic tools. This narrative review article aimed to understand potential benefits and limitations of RNAi technique for clinical application and in vivo studies through reading the articles published during the recent 3 years.
MATERIALS AND METHODS: Medline database was searched by using 'siRNA' or 'RNAi' and 'in vivo' with limits of dates 'published in the last 3 years', language 'English' and article type 'clinical trial' for obtaining articles on in vivo studies on the use of RNAi technique. Characteristics of clinical trials on siRNA registered at the http://www.ClinicalTrials.gov were analysed.
RESULTS: The only three clinical studies published so far and many in vivo studies in animals showed that the RNAi technique is safe and effective in treatment of cancers of many organ/systems and various other diseases including viral infection, arterial restenosis and some hereditary diseases with considerable benefits such as high specificity, many possible routes of administration and possibility of silencing multiple genes at the same time. Limitations and uncertainty include efficiency of cellular uptake, specific guidance to the target tissue or cell, long-term safety, sustained efficacy and rapid clearance from the body.
CONCLUSIONS: RNAi technique will become an important and potent weapon for fighting against various diseases. RNAi technique has benefits and limitations in its potential clinical applications. Overcoming the obstacles is still a formidable task.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964680     DOI: 10.1111/j.1365-2362.2010.02400.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  28 in total

Review 1.  Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.

Authors:  Andrew B Hill; Mingfu Chen; Chih-Kuang Chen; Blaine A Pfeifer; Charles H Jones
Journal:  Trends Biotechnol       Date:  2015-12-23       Impact factor: 19.536

2.  Implementation of a chronic unilateral intraparenchymal drug delivery system in a swine model.

Authors:  Inyong Kim; Seungleal Paek; Brian D Nelson; Emily J Knight; Michael P Marsh; Allan J Bieber; Kevin E Bennet; Kendall H Lee
Journal:  J Neurosci Methods       Date:  2014-01-31       Impact factor: 2.390

3.  Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Authors:  David A Stein; Stuart T Perry; Michael D Buck; Christopher S Oehmen; Matthew A Fischer; Elizabeth Poore; Jessica L Smith; Alissa M Lancaster; Alec J Hirsch; Mark K Slifka; Jay A Nelson; Sujan Shresta; Klaus Früh
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

4.  Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays.

Authors:  Maria Fernanda Lara; Emilio González-González; Tycho J Speaker; Robyn P Hickerson; Devin Leake; Leonard M Milstone; Christopher H Contag; Roger L Kaspar
Journal:  Hum Gene Ther       Date:  2012-06-05       Impact factor: 5.695

5.  Albumin-Binding Aptamer Chimeras for Improved siRNA Bioavailability.

Authors:  Jonah C Rosch; Ella N Hoogenboezem; Alexander G Sorets; Craig L Duvall; Ethan S Lippmann
Journal:  Cell Mol Bioeng       Date:  2022-01-24       Impact factor: 2.321

6.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

Authors:  Mar Creixell; Nicholas A Peppas
Journal:  Nano Today       Date:  2012-08-01       Impact factor: 20.722

Review 7.  Bioreducible polymers for therapeutic gene delivery.

Authors:  Young Sook Lee; Sung Wan Kim
Journal:  J Control Release       Date:  2014-04-16       Impact factor: 9.776

Review 8.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer.

Authors:  Jonathan E Zuckerman; Mark E Davis
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

9.  Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines.

Authors:  Laura V Bownes; Adele P Williams; Raoud Marayati; Colin H Quinn; Sara C Hutchins; Jerry E Stewart; Trung Vu; Juliet L Easlick; Elizabeth Mroczek-Musulman; David K Crossman; Joshua C Anderson; Christopher D Willey; Pran K Datta; Elizabeth A Beierle
Journal:  Cancers (Basel)       Date:  2021-06-26       Impact factor: 6.639

Review 10.  Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Enzo Di Fabrizio; Elisabetta Ferretti; Silverio Tomao; Alberto Gulino
Journal:  Int J Nanomedicine       Date:  2012-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.